Skip to content

CRMD: Held by 3 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›CorMedix Inc. (CRMD)

CorMedix Inc.

CRMD

Held by 3 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

3 funds opened new positions. Next phase2 readout (CRMD-001-Deferiprone): Jun 2011. Short interest: 21.0% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: Joseph TodiscoIPO: 2010Website ↗

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

4.5/10

3 funds opened new positions●●

No recent insider activity●●

Phase3 readout expected Jan 2027●●

Held by 3 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

3 specialist funds hold CRMD with a Phase 3 in 263 days for (taurolidine and heparin) catheter lock solution (Central Line Associated Blood Stream Infections (CLABSI))

Driehaus Capital Deerfield Management Deep Track Capital

Fund Holdings

3 fund convergence

Driehaus Capital

Deerfield ManagementHeld 2Q ↓

Deep Track CapitalHeld 2Q ↑

Position history (shares)

Deerfield Management

2Q

Deep Track Capital

2Q

3 quarters

Position Trend

Aug 14, 2025

$3.8M

1 fund

Nov 14, 2025

$44.5M

2 funds

Feb 13, 2026

$61.3M

1 fund

Feb 17, 2026

$12.9M

1 fund

+240% total institutional value over 4 quarters

Short Interest

High short interest

Short Shares

16.22M

Change

+2.8%

Days to Cover

16.0

% of Float

21.0%

Settlement

Apr 30, 2026

Short interest over 5 periods

Catalysts

Phase 2Q2 2011CRMD-001-DeferiproneContrast-Induced Acute Kidney InjuryNCT01146925

Primary: Biomarker evidence of Acute Kidney injury (8 Days)Enrollment:Target 60Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2013deferiproneAcute Kidney InjuryNCT01391520

Primary: A composite of renal and cardiovascular clinical events occurring through Day 90 (Day 90 following index cardiac catheterization)0RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2018NeutrolinKidney Failure, Chronic, Catheter-Related InfectionsNCT02651428

Primary: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD): Final Analysis (The event time was the number of days from randomization until the occurrence of a CAC-Adjudicated CRBSI or until the subject was censored. The mean participant duration of exposure to study drug was 174 days (range 4-884 days).)Enrollment:806/806Sites: 5RANDOMIZED, TRIPLE, PREVENTION

Phase 3Q1 2027(taurolidine and heparin) catheter lock solutionCentral Line Associated Blood Stream Infections (CLABSI)NCT06822426

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13GDeep Track Capital6.3%Dec 1, 2025

Position Details

Driehaus CapitalEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

6 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

EHAB1 fund NVST1 fund MMSI1 fund ALNY1 fund DAWN1 fund DXCM1 fund BBNX1 fund IDYA1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: